MARKET

ENGN

ENGN

enGene Holdings Inc.
NASDAQ
4.000
+0.040
+1.01%
After Hours: 3.800 -0.2 -5.00% 18:59 04/17 EDT
OPEN
3.900
PREV CLOSE
3.960
HIGH
4.050
LOW
3.810
VOLUME
14.12K
TURNOVER
--
52 WEEK HIGH
16.62
52 WEEK LOW
3.500
MARKET CAP
203.91M
P/E (TTM)
-2.6188
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (0407-0411)?
Weekly Report · 6d ago
Weekly Report: what happened at ENGN last week (0331-0404)?
Weekly Report · 04/07 12:22
Weekly Report: what happened at ENGN last week (0324-0328)?
Weekly Report · 03/31 12:39
Weekly Report: what happened at ENGN last week (0317-0321)?
Weekly Report · 03/24 12:22
Weekly Report: what happened at ENGN last week (0310-0314)?
Weekly Report · 03/17 12:38
enGene Holdings Is Maintained at Overweight by Morgan Stanley
Dow Jones · 03/11 14:33
enGene Holdings Price Target Cut to $34.00/Share From $37.00 by Morgan Stanley
Dow Jones · 03/11 14:33
Morgan Stanley Maintains Overweight on enGene Holdings, Lowers Price Target to $34
Benzinga · 03/11 14:23
More
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.